The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF MRD Webinar


The Cancer Drug Development Forum organized a live webinar on the topic of Measurable Residual Disease in Acute Myeloid Leukemia on Thursday 24 February 2022 at 17:00 (CET). This webinar was composed of a 25-minute lecture given by Dr. Christopher Hourigan followed by a 30-minute discussion session.


Measurable residual disease (MRD) in adult patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT) has been identified as an important prognostic factor. Recent evidence demonstrates that intervention on high-risk patients testing positive may be able to reduce relapse and improve survival. Discrepancies between AML MRD detected by flow cytometry and molecular/genomic testing are possible, as illustrated by patient-personalized whole-genome-informed single-cell DNA and antibody-oligonucleotide sequencing. Finally, remaining questions regarding the clinical utility of AML MRD in alloHCT will lead to proposals for future clinical protocols.



Dr. Christopher Hourigan DM DPhil FACP FRCP is Chief of the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). He is co-director of the trans-NIH Myeloid Malignancies Program, part-time Associate Professor of Oncology at Johns Hopkins School of Medicine, and a member of the Leukemia program of Johns Hopkins Hospital. Dr. Hourigan’s research focuses measurable residual disease (MRD) in acute myeloid leukemia (AML). He is co-PI of the upcoming fNIH Industry-FDA-Academic-NIH biomarkers consortium on AML MRD, co-lead of genomics for the European Leukemia Network (ELN) International Consensus Guidelines committee on MRD in AML, co-chair of the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR, 2020-2025), co-chair of the laboratory committee of the NCI Myeloid Malignancies Precision Medicine Initiative (“MyeloMATCH”) and member of the American Society of Hematology (ASH) Clinical Guidelines Committee for AML.

After graduation from Oxford University, he completed postdoctoral training in London and at Johns Hopkins, and is board-certified in Medicine, Oncology and Hematology. Dr. Hourigan was elected to Alpha Omega Alpha and fellowship of the Royal College of Physicians and was awarded the Young Physician-Scientist Award from the American Society for Clinical Investigation and, in 2019, the Presidential Early Career Award for Scientists and Engineers (PECASE).

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70